Product
ampreloxetine
Aliases
TD-9855
2 clinical trials
4 indications
Indication
Multiple System AtrophyIndication
Parkinson's DiseaseIndication
Pure Autonomic FailureClinical trial
A Multicenter, Non-interventional, Observational, Prospective Study to Assess Hypotension in Patients With Primary Immunodeficiency Disease Treated With Bivigam™ (Human 10%) or Other Commercial Human 10% Immune Globulin (Intravenous) (IGIV) Products During Infusion and up to 72 Hours Post InfusionStatus: Active (not recruiting), Estimated PCD: 2022-12-31
Clinical trial
A Phase 3, 182-week, Open-Label, Extension Study to Investigate the Safety and Tolerability of TD-9855 in Treating Symptomatic Neurogenic Orthostatic Hypotension (Symptomatic nOH) in Subjects With Primary Autonomic FailureStatus: Terminated, Estimated PCD: 2021-11-12